The increasing burden of HIV-associated malignancies in resource-limited regions

Annual Review of Medicine

Volumn 62, Issue , 2011, Pages 157-170

  Casper, Corey ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

cancer; hepatocellular carcinoma; HIV; Kaposi sarcoma; lymphoma; sub Saharan Africa

Indexed keywords

ANTIRETROVIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CANCER INCIDENCE; CANCER PREVENTION; CARCINOGENESIS; COMORBIDITY; EPIDEMIOLOGICAL DATA; EPSTEIN BARR VIRUS; HEALTH CARE POLICY; HEALTH CARE UTILIZATION; HEALTH PROMOTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED MALIGNANCY; HODGKIN DISEASE; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOPATHOGENESIS; KAPOSI SARCOMA; LIVER CELL CARCINOMA; LUNG CANCER; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGRAM DEVELOPMENT; RISK ASSESSMENT; RISK FACTOR; SMOKING CESSATION; SOUTH AFRICA; UTERINE CERVIX CANCER; VIRUS REPLICATION; WART VIRUS;

AFRICA SOUTH OF THE SAHARA; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CARCINOMA, HEPATOCELLULAR; CELL TRANSFORMATION, NEOPLASTIC; COMORBIDITY; FEMALE; HIV INFECTIONS; HUMANS; INCIDENCE; LIVER NEOPLASMS; LYMPHOMA; MALE; NEOPLASMS; PREVALENCE; PUBLIC HEALTH PRACTICE; SARCOMA, KAPOSI; VIRUS REPLICATION;

EID: 79551591482     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev-med-050409-103711     Document Type: Article

References (72)

1. Center for Disease Control. 1981. Kaposi's sarcoma and Pneumocystis pneumonia among homosexual men-New York City and California. MMWR Morb. Mortal. Wkly. Rep. 30:305-8
2. Hymes KB, Cheung T, Greene JB, et al. 1981. Kaposi's sarcoma in homosexual men-a report of eight cases. Lancet 2:598-600
3. Grulich AE, van Leeuwen MT, Falster MO, et al. 2007. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 370:59-67
4. Bonnet F, Lewden C, May T, et al. 2004. Malignancy-related causes of death in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy. Cancer 101:317-24
5. Eltom MA, Jemal A, Mbulaiteye SM, et al. 2002. Trends in Kaposi's sarcoma and non-Hodgkin's lym-phoma incidence in the United States from 1973 through 1998. J. Natl. Cancer Inst. 94:1204-10
6. Engels EA, Biggar RJ, Hall HI, et al. 2008. Cancer risk in people infected with human immunodeficiency virus in the United States. Int. J. Cancer 123:187-94
7. van Leeuwen MT, Vajdic CM, Middleton MG, et al. 2009. Continuing declines in some but not all HIV-associated cancers in Australia after widespread use of antiretroviral therapy. AIDS 23:2183-90
8. Patel P, Hanson DL, Sullivan PS, et al. 2008. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann. Intern. Med. 148:728-36
9. Crum-Cianflone N, Hullsiek KH, Marconi V, et al. 2009. Trends in the incidence of cancers among HIV-infected persons and the impact of antiretroviral therapy: a 20-year cohort study. AIDS 23:41-50
10. International Collaboration on HIV and Cancer. 2000. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J. Natl. Cancer Inst. 92:1823-30
11. Gates AE, Kaplan LD. 2002. AIDS malignancies in the era of highly active antiretroviral therapy. Oncology 16:657-65; discussion 65, 68-70
12. Powles T, Robinson D, Stebbing J, et al. 2009. Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection. J. Clin. Oncol. 27:884-90
13. Shiels MS, Cole SR, Kirk GD, et al. 2009. A meta-analysis of the incidence of non-AIDS cancers in HIV-infected individuals. J. Acquir. Immune Defic. Syndr. 52:611-22
14. Aaron L, Lidove O, Yousry C, et al. 2002. Human herpesvirus 8-positive Castleman disease in human immunodeficiency virus-infected patients: the impact of highly active antiretroviral therapy. Clin. Infect. Dis. 35:880-82
15. Bower M, Nelson M, Young AM, et al. 2005. Immune reconstitution inflammatory syndrome associated with Kaposi's sarcoma. J. Clin. Oncol. 23:5224-28
16. Connick E, Kane MA, White IE, et al. 2004. Immune reconstitution inflammatory syndrome associated with Kaposi sarcoma during potent antiretroviral therapy. Clin. Infect. Dis. 39:1852-55
17. Crane HM, Deubner H, Huang JC, et al. 2005. Fatal Kaposi's sarcoma-associated immune reconstitution following HAART initiation. Int. J. STD AIDS 16:80-83
18. Kawsar M. 2005. Fatal Kaposi's sarcoma-associated immune reconstitution following highly active an-tiretroviral therapy. Int. J. STD AIDS 16:582-83
19. Leidner RS, Aboulafia DM. 2005. Recrudescent Kaposi's sarcoma after initiation of HAART: a manifestation of immune reconstitution syndrome. AIDS Patient Care STDs 19:635-44
20. Maurer T, Ponte M, Leslie K. 2007. HIV-associated Kaposi's sarcoma with a high CD4 count and a low viral load. N. Engl. J. Med. 357:1352-53
21. Stein L, Urban MI, O'Connell D, et al. 2008. The spectrum of human immunodeficiency virus-associated cancers in a South African black population: results from a case-control study, 1995-2004. Int. J. Cancer 122:2260-65
22. Mutalima N, Molyneux EM, Johnston WT, et al. 2010. Impact of infection with human immunodeficiency virus-1 (HIV) on the risk of cancer among children in Malawi-preliminary findings. Infect. Agent. Cancer 5:5
23. Dhir A, Sawant S, Dikshit R, et al. 2008. Spectrum of HIV/AIDS related cancers in India. Cancer Causes Control 19:147-53
24. Mbulaiteye SM, Katabira ET, Wabinga H, et al. 2006. Spectrum of cancers among HIV-infected persons in Africa: the Uganda AIDS-Cancer Registry Match Study. Int. J. Cancer 118:985-90
25. Sasco AJ, Jaquet A, Boidin E, et al. 2010. The challenge of AIDS-related malignancies in sub-Saharan Africa. PLoS ONE 5:e8621
26. Parkin DM, Nambooze S, Wabwire-Mangen F, et al. 2010. Changing cancer incidence in Kampala, Uganda, 1991-2006. Int. J. Cancer 126:1187-95
27. Guech-Ongey M, Engels EA, Goedert JJ, et al. 2008. Elevated risk for squamous cell carcinoma of the conjunctiva among adults with AIDS in the United States. Int. J. Cancer 122:2590-93
28. Biggar RJ, Chaturvedi AK, Goedert JJ, et al. 2007. AIDS-related cancer and severity of immunosuppres-sion in persons with AIDS. J. Natl. Cancer Inst. 99:962-72
29. Bruyand M, Thiebaut R, Lawson-Ayayi S, et al. 2009. Role of uncontrolled HIV RNA level and immunodeficiency in the occurrence of malignancy in HIV-infected patients during the combination antiretroviral therapy era: Agence Nationale de Recherche sur le Sida (ANRS) CO3 Aquitaine Cohort. Clin. Infect. Dis. 49:1109-16
30. Zoufaly A, Stellbrink HJ, Heiden M, et al. 2009. Cumulative HIV viremia during highly active antiretro-viral therapy is a strong predictor of AIDS-related lymphoma. J. Infect. Dis. 200:79-87
31. Engels EA, Biggar RJ, Marshall VA, et al. 2003. Detection and quantification of Kaposi's sarcoma-associated herpesvirus to predict AIDS-associated Kaposi's sarcoma. AIDS 17:1847-51
32. Mendy ME, Welzel T, Lesi OA, et al. 2010. Hepatitis B viral load and risk for liver cirrhosis and hepa-tocellular carcinoma in The Gambia, West Africa. J. Viral Hepat. 17:115-22
33. Chen CJ, Yang HI, Su J, et al. 2006. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295:65-73
34. Nishiguchi S, Kuroki T, Nakatani S, et al. 1995. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 346:1051-55
35. Casper C, Krantz E, Selke S, et al. 2007. Frequent and asymptomatic oropharyngeal shedding of human herpesvirus 8 among immunocompetent men. J. Infect. Dis. 195:30-36
36. Johnston C, Orem J, Okuku F, et al. 2009. Impact of HIV infection and Kaposi sarcoma on human herpesvirus-8 mucosal replication and dissemination in Uganda. PLoS ONE 4:e4222
37. Martin MP, Carrington M. 2005. Immunogenetics of viral infections. Curr. Opin. Immunol. 17:510-16
38. Brown EE, Fallin MD, Goedert JJ, et al. 2006. Host immunogenetics and control of human herpesvirus-8 infection. J. Infect. Dis. 193:1054-62
39. World Health Organization. 2009. Cancer. In Fact Sheets, ed. World Health Organization. Geneva: World Health Organ.
40. World Health Organization Regional Office for Africa. 2006. The Health of the People: The African Regional Health Report. Brazzaville, Republic of Congo: World Health Organ., Reg. Off. Afr. xxv, 170 pp.
41. Coggin WL, Ryan CA, Holmes CB. 2010. Role of the US President's Emergency Plan for AIDS Relief in responding to tuberculosis and HIV coinfection. Clin. Infect. Dis. 50(Suppl. 3):S255-59
42. Mwanahamuntu MH, Sahasrabuddhe VV, Pfaendler KS, et al. 2010. Implementation of 'see-and-treat' cervical cancer prevention services linked to HIV care in Zambia. AIDS. E-pub ahead of print. doi: 10.1097/QAD. 0b013e3283236e11
43. President's Emergency Plan for AIDS Relief. 2010. Global Health Initiative. Available at http://www.pepfar.gov/ghi/index.htm, accessed May 26, 2010
44. Kitahata MM, Gange SJ, Abraham AG, et al. 2009. Effect of early versus deferred antiretroviral therapy for HIV on survival. N. Engl. J. Med. 360:1815-26
45. World Health Organization. 2009. Rapid Advice: Antiretroviral Therapy for HIV Infection in Adults and Adolescents. Geneva: World Health Organ.
46. Friedl AC, Ledergerber B, Flepp M, et al. 2001. Response to first protease inhibitor- and efavirenz-containing antiretroviral combination therapy. The Swiss HIV Cohort Study. AIDS 15:1793-800
47. Bani-Sadr F, Fournier S, Molina JM. 2003. Relapse of Kaposi's sarcoma in HIV-infected patients switching from a protease inhibitor to a non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy regimen. AIDS 17:1580-81
48. Sgadari C, Barillari G, Toschi E, et al. 2002. HIV protease inhibitors are potent antiangiogenic molecules and promote regression of Kaposi sarcoma. Nat. Med. 8:225-32
49. Gills JJ, Lopiccolo J, Tsurutani J, et al. 2007. Nelfinavir, a lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo. Clin. Cancer Res. 13:5183-94
50. Portsmouth S, Stebbing J, Gill J, et al. 2003. A comparison of regimens based on non-nucleoside reverse transcriptase inhibitors or protease inhibitors in preventing Kaposi's sarcoma. AIDS 17:F17-22
51. Grabar S, Abraham B, Mahamat A, et al. 2006. Differential impact of combination antiretroviral therapy in preventing Kaposi's sarcoma with and without visceral involvement. J. Clin. Oncol. 24:3408-14
52. TM (raltegravir) 400 mg for treatment of HIV (NDA 22-145). Presented at FDA Antiviral Drugs Advisory Comm. Meet., Rockville, MD
53. Nozza S, Galli L, Visco F, et al. 2010. Raltegravir, maraviroc, etravirine: an effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experience. AIDS 24:924-28
54. Sikora MJ, Rae JM, Johnson MD, et al. 2010. Efavirenz directly modulates the oestrogen receptor and induces breast cancer cell growth. HIV Med. E-pub ahead of print. doi: 10.1111/j.1468-1293.2010.00831.x
55. Chow WA, Jiang C, Guan M. 2009. Anti-HIV drugs for cancer therapeutics: back to the future? Lancet Oncol. 10:61-71
56. Chang M-H, Chen C-J, Lai M-S, et al. 1997. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N. Engl. J. Med. 336:1855-59
57. van den Berg R, van Hoogstraten I, van Agtmael M. 2009. Non-responsiveness to hepatitis B vaccination in HIV seropositive patients; possible causes and solutions. AIDS Rev. 11:157-64
58. Garland SM, Hernandez-Avila M, Wheeler CM, et al. 2007. Quadrivalent vaccine against human papil-lomavirus to prevent anogenital diseases. N. Engl. J. Med. 356:1928-43
59. Sokal EM, Hoppenbrouwers K, Vandermeulen C, et al. 2007. Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults. J. Infect. Dis. 196:1749-53
60. Finerty S, Tarlton J, Mackett M, et al. 1992. Protective immunization against Epstein-Barr virus-induced disease in cottontop tamarins using the virus envelope glycoprotein gp340 produced from a bovine papil-lomavirus expression vector. J. Gen. Virol. 73(Pt 2):449-53
61. Dialyna IA, Graham D, Rezaee R, et al. 2004. Anti-HHV-8/KSHV antibodies in infected individuals inhibit infection in vitro. AIDS 18:1263-70
62. Kimball LE, Casper C, Koelle DM, et al. 2004. Reduced levels of neutralizing antibodies to Kaposi sarcoma-associated herpesvirus in persons with a history of Kaposi sarcoma. J. Infect. Dis. 189:2016-22
63. Pestka JM, Zeisel MB, Blaser E, et al. 2007. Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc. Natl. Acad. Sci. USA 104:6025-30
64. Blankinship DG. 2009. American cancer doctors reach out to Africa. In Boston Herald. Boston, MA Available at: http://bh.heraldinteractive.com/ business/healthcare/view.bg?articleid=1207587&srvc= business&position= recent, accessed July 17, 2010
65. 2002. Cancer incidence in five continents. Volume VIII. IARC Sci. Publ. 155:1-781
66. Osmond DH, Buchbinder S, Cheng A, et al. 2002. Prevalence of Kaposi sarcoma-associated herpesvirus infection in homosexual men at beginning of and during the HIV epidemic. JAMA 287:221-25
67. Bihl F, Berger C, Chisholm JVI, et al. 2009. Cellular immune responses and disease control in acute AIDS-associated Kaposi's sarcoma. AIDS 23:1918-22
68. Bihl F, Mosam A, Henry LN, et al. 2007. Kaposi's sarcoma-associated herpesvirus-specific immune re-constitution and antiviral effect of combined HAART/chemotherapy in HIV clade C-infected individuals with Kaposi's sarcoma. AIDS 21:1245-52
69. Casper C, Wald A. 2007. The use of antiviral drugs in the prevention and treatment of Kaposi sarcoma, multicentric Castleman disease and primary effusion lymphoma. Curr. Top. Microbiol. Immunol. 312:289-307
70. Krown SE, Testa MA, Huang J. 1997. AIDS-related Kaposi's sarcoma: prospective validation of the AIDS Clinical Trials Group staging classification. AIDS Clinical Trials Group Oncology Committee. J. Clin. Oncol. 15:3085-92
71. Minkoff H, Zhong Y, Burk RD, et al. 2010. Influence of adherent and effective antiretroviral therapy use on human papillomavirus infection and squamous intraepithelial lesions in human immunodeficiency virus-positive women. J. Infect. Dis. 201:681-90
72. Boyle P, Levin B, International Agency for Research on Cancer. 2008. World Cancer Report 2008. Lyon: IARC Press